Sponsor content
108 result(s) found, displaying 1 to 10
-
Australian public assessment report (AusPar)Livdelzi (seladelpar) has been approved for the treatment of primary biliary cholangitis (PBC) in combination with ursodeoxycholic acid (UDCA) in adults who have an inadequate response to UDCA alone, or as monotherapy in those unable to tolerate UDCA.
-
Apr-2026Prescription medicine evaluationActive ingredient: sacituzumab govitecan.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for LIVDELZI seladelpar 10 mg capsule bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YEYTUO lenacapavir (as sodium) 300 mg tablet bottle.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for YEYTUO lenacapavir (as sodium) 463.5 mg/1.5 mL solution for injection vial.
-
Australian public assessment report (AusPar)Hepcludex (bulevirtide) is approved for treatment of chronic hepatitis delta virus (HDV) infection in adults with compensated liver disease.
-
Prescription medicine decision summaryLivdelzi (seladelpar) is approved to treat primary biliary cholangitis (PBC) in adults in combination with ursodeoxycholic acid (UDCA) when UDCA alone isn't effective, or on its own if UDCA can’t be tolerated.
-
Prescription medicine registrationActive ingredients: seladelpar lysine.
-
Prescription medicine registrationActive ingredients: lenacapavir sodium.
-
ARTGAustralian Register of Therapeutic Goods (ARTG) information for SUNLENCA lenacapavir (as sodium) 300 mg film coated tablet bottle.